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Abstract: Obliterative bronchiolitis (OB) and Bronchiolitis Obliterans Syndrome (BOS) are frequent complications in the 
lung transplant recipient, and are the leading cause of mortality after transplantation. The mechanisms responsible for OB 
remain elusive, but inﬂ  ammatory and tissue remodeling responses are implicated. We hypothesized that alterations in mark-
ers of tissue remodeling in BALF of lung transplant recipients could predict development of OB. To test this, we identiﬁ  ed 
13 lung transplant recipients who developed both BOS and histologic OB (OB group) at median post-operative day (POD) 
485 (range 73–2070). Bronchoalveolar lavage ﬂ  uid (BALF) was obtained at median POD 387 (range 45–2205), which 
preceded the onset of OB and BOS by a median of 140 days (range 60–365). As a control, BALF was also obtained from 
a group of 21 stable recipients without OB (non-OB group) at median POD 335 (range 270–395). BALF was examined for 
gelatinolytic activity, ﬁ  bronectin gene transcription, and transforming growth factor-β1 (TGF-β1) expression. Gelatin 
zymography of BALF from the OB group showed increased matrix metalloproteinase-9 (MMP-9) activity over that of the 
non-OB group (p < 0.005). Similarly, BALF from the OB group induced greater ﬁ  bronectin expression in ﬁ  broblasts com-
pared to the non-OB group (p < 0.03). The induction of ﬁ  bronectin also correlated with the amount of TGF-β1 protein in 
BALF (r = 0.71) from the OB group. We conclude that activation of tissue remodeling precedes the onset of OB, and 
analysis of gelatinolytic and/or ﬁ  bronectin-inducing activity in BALF can serve as an early, pre-clinical marker for OB.
Keywords: tissue remodeling, transforming growth factor-beta, ﬁ  bronectin, matrix metalloproteinase, lung transplant
Introduction
Over the past twenty years, lung transplantation (LTX) has evolved into a viable treatment option for 
patients with end-stage lung disease resulting from a variety of pulmonary insults. However, allograft 
rejection with the development of obliterative bronchiolitis (OB) remains the single greatest impedi-
ment to long-term survival following lung transplantation (Estenne and Hertz, 2002). The diagnosis of 
OB, which complicates nearly 60% of lung allografts, is made histologically with the demonstration 
of obstructing intraluminal plugs of ﬁ  bromyxoid tissue in terminal bronchioles. This entity becomes 
more prevalent with an increasing interval since the transplant procedure (Sundaresan et al. 1995). 
Often accompanied by recurrent airway infections (Paradis et al. 1993), if unabated, OB ultimately 
results in progressive ventilatory insufﬁ  ciency and death. The clinical correlate of OB is termed the 
bronchiolitis obliterans syndrome (BOS) and is manifested in the allograft recipient by a reduction in 
forced expiratory volume in 1 second (FEV1) of at least 20% in the absence of other identiﬁ  able causes 
(Cooper et al. 1993).
Obliterative bronchiolitis may have an inhomogeneous distribution in the allograft. Consequently, 
the sensitivity of transbronchial lung biopsy for detecting OB approaches only 15%–40%, even with a 
high clinical suspicion (Kramer et al. 1993; Ladowski et al. 1993). Once identiﬁ  ed, OB typically responds 
poorly to augmented immunosuppression. Because the histologic conﬁ  rmation of OB may be difﬁ  cult, 
alternative means have been investigated in an attempt to identify surrogate markers for OB. Perhaps, 
the identiﬁ  cation of such markers may be more useful should they accurately predict the later develop-
ment of OB at a stage when directed therapy may be more successful.
Most studies on the pathogenesis of OB have concentrated on the role of cellular and/or humoral 
allogeneic immune responses after LTX (Henke et al. 1999; Leonard et al. 2002). Other studies point to 352
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inﬂ  ammatory mediators as important players in the 
pathogenesis of OB (De Andrade et al. 2000; 
DiGiovine et al. 1996; Reynaud-Gaubert et al. 
2002). More recently, attention has been given to 
factors that control the tissue remodeling or ﬁ  bro-
proliferative response of the lung to injury. This 
tissue remodeling response is responsible for the 
accumulation of ﬁ  broblasts and the excess deposi-
tion of connective tissue matrices within the airway 
lumen causing the progressive airﬂ  ow limitation 
characteristic of OB (Roman, 1998). Little is known 
about the factors that trigger and maintain this tis-
sue remodeling response in LTX recipients.
From our unpublished observations, we found 
evidence for differential tissue remodeling activity 
in allografts of lung transplant recipients. Speciﬁ  -
cally, gelatinolytic activity, a marker of connective 
tissue degrading capability, was increased in the 
bronchoalveolar lavage ﬂ  uid of all recipients during 
the ﬁ  rst 3 months following transplantation. This 
activity, however, remained elevated only in those 
recipients who met criteria for bronchiolitis oblit-
erans syndrome. Based on these preliminary data, 
we subsequently analyzed lung lavage ﬂ  uid from 
34 lung transplant recipients whose allograft func-
tion was clearly deﬁ  ned with respect to the presence 
of OB and BOS. Lavage ﬂ  uid obtained before either 
the clinical or histologic onset of OB/BOS was 
analyzed for three markers of tissue remodeling; 
namely, gelatinolytic activity, induction of ﬁ  bro-
nectin expression in ﬁ  broblasts, and the expression 
of the profibrotic growth factor, transforming 
growth factor–β1 (TGF-β1). In addition, we exam-
ined the lavage ﬂ  uid for cytokine markers of inﬂ  am-
mation as potential precursors to OB.
Materials and Methods
Study subjects
Study subjects included lung transplant recipients 
who were followed at the University of Pittsburgh 
Medical Center, Pittsburgh, PA between January 1, 
1995 and December 31, 2000. Recipients, aged 
from 18 to 65 years old, received a standard main-
tenance immunosuppressive regimen which con-
sisted of a calcineurin inhibitor, either cyclosporine 
or tacrolimus. Cyclosporine doses were adjusted 
to maintain whole blood trough levels of between 
200 and 250 ng/ml, while tacrolimus doses were 
adjusted to maintain whole blood trough levels 
between 10 and 20 ng/ml. In addition to the 
calcineurin inhibitor, the maintenance immunosup-
pressive regimen also consisted of azathioprine 
(0.5 to 1 mg/kg per day), to maintain a white blood 
cell count above 5,000/mm
3; and prednisone, 
which was slowly tapered to a nadir of zero to 
5 mg per day. Episodes of acute cellular allograft 
rejection were treated with intravenous methyl-
prednisolone 1 gram per day for 3 consecutive 
days. The diagnoses of OB and BOS were estab-
lished according to the criteria of the International 
Society of Heart and Lung Transplantation (Cooper 
et al. 1993).
Bronchoalveolar lavage ﬂ  uid collection
After obtaining informed consent, bronchoalveolar 
lavage ﬂ  uid (BALF) was collected, and a database 
consisting of contemporaneous clinical informa-
tion was compiled. Samples were obtained during 
routine surveillance of lung allografts according 
to the following schedule: every 3 months dur-
ing the ﬁ  rst postoperative year, every 4 months 
during the second postoperative year, every 
6 months during the third postoperative year, and 
once each year beginning with the fourth postop-
erative year. Additionally, data and BALF were 
collected when bronchoscopy was performed for 
any change in the recipient’s clinical and/or func-
tional status. Bronchoalveolar lavage was per-
formed by instilling a total of 200cc of normal 
saline into a subsegment of the lingula or the right 
middle lobe. The database and BALF samples were 
transferred to and analyzed at Emory University 
(by D.N.). The study was approved by the institu-
tional review boards of the University of  Pittsburgh 
and Emory University.
Protein determination
To ensure valid comparisons of BALF analyses, 
total protein concentration was determined using 
the Protein Assay Dye Reagent according to 
manufacturer instructions (Bio-Rad, Hercules, 
CA). Aliquots of BALF containing equivalent 
amounts of protein were subsequently used for the 
testing described below.
Gelatin zymography
BALF was fractionated by electrophoresis in 8% 
SDS-polyacrylamide gels containing 0.3 mg/ml 
of gelatin (Sigma, St. Louis, MO) under nonreduc-
ing conditions (Rivera-Marrero et al. 2000). 353
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Prestained molecular weight markers (Amersham 
Biosciences, Piscataway, NJ) along with a puriﬁ  ed 
matrix metalloproteinase (MMP)-9 standard 
(EMD Biosciences, La Jolla, CA) were included 
to estimate the molecular weight of the gelatino-
lytic bands. The gels were washed with 2.5% 
Triton X-100, incubated overnight at 37 
oC in 
incubation buffer (50mM Tris pH 7.5, 5 mM 
CaCl2), stained with 0.25% Coomassie blue R-250 
(Sigma Chemical Company, St. Louis, MO) in 
water/methanol/acetic acid (45:45:10), and 
destained with 50% methanol in water. Gelatino-
lytic activities, detected as a transparent band in 
the remaining blue-stained gel, were analyzed by 
densitometry.
Cell culture and ﬁ  bronectin gene 
expression
To study the ability of BALF to stimulate ﬁ  bro-
nectin expression, the full length fibronectin 
promoter connected to a luciferase reporter vector, 
pFN(1.2 kb)LUC, was introduced into murine 
NIH3T3 fibroblasts from the American Type 
Culture Collection (CRL #1658; Rockville, MD) 
via electroporation to create stable transfectants 
as previously described (Michaelson et al. 2002). 
Fibroblasts were maintained at 37 °C in a 5% CO2 
atmosphere in Dulbecco’s modified Eagle’s 
medium (Mediatech, Herndon, VA) supplemented 
with 10% heat-inactivated fetal bovine serum 
(FBS) and 1% antibiotic-antimycotic (100 U/ml 
penicillin G sodium, 100 U/ml streptomycin sul-
fate, and 0.25 g/ml amphotericin B). The cells 
were harvested by trypsinization with 2.5X tryp-
sin and 5.3 mM EDTA (Sigma), washed with PBS, 
plated at 1.5 × 10
5 cells/ml in 6 well tissue culture 
dishes, and grown to near conﬂ  uence. Following 
serum starvation for 24 hours and incubation with 
300μl aliquots of BALF with equal protein con-
tent in 700 μl serum-free media (Mediatech) for 
72 hours, fibroblasts were harvested by cell 
scraper, washed with PBS, resuspended in 100 μl 
of cell lysis buffer (Promega), and sonicated. 
Light intensity of a 10-μl aliquot of cell lysate 
was tested by adding 50 μl of luciferase assay 
reagent (Promega, Madison, WI) and measured 
using a ThermoLabsystems Luminoskan Ascent 
microtiter plate luminometer. Experiments were 
performed in duplicate and repeated, with results 
recorded as luciferase units, normalized to total 
protein content.
Enzyme linked immunosorbent assay
TGF-β1 in BALF was assayed in duplicate by 
sandwich enzyme-linked immunosorbent assay 
using the TGF-β1 Emax
® ImmunoAssay System 
(Promega, Madison, WI) according to manufac-
turer protocol. Brieﬂ  y, 96-well ﬂ  at-bottom plates 
(Nalge Nunc International, Rochester, NY) were 
coated with TGF-β1 coating monoclonal antibody 
overnight at 4 °C, blocked with Block Buffer, and 
incubated with BALF for 90 minutes. Plates were 
then incubated with a second anti-TGF-β1 poly-
clonal antibody, washed with tris-buffered saline 
with 0.05% Tween-20 (Sigma, St. Louis, MO), and 
incubated with TGF-β1 HRP Conjugate. A 3-3',5,5'-
tetramethylbenzidine/peroxidase reagent solution 
was added to develop color. The reaction was ter-
minated with 1 N HCl and the optical density was 
measured at 450 nm in an AD 340 Plate Reader 
(Beckman Coulter, Fullerton, CA). A standard 
curve was generated using serial dilutions of 
known amounts of TGF-β1.
Detection of cytokine protein in BALF
A Multiplex Bead Immunoassay, that uses micro-
spheres labeled with unique ﬂ  uorophores in a 
single well of a ﬁ  lter bottomed ELISA plate, was 
used to analyze cytokine protein levels in BALF 
samples. A 10 plex-kit (Biosource, Camirillo, CA) 
was used that allowed for simultaneous detection 
of: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, 
IFN-γ, GM-CSF and TNF-α. Well ﬁ  lters were pre-
washed and 50 μl of 1:1 diluted sample are applied 
to each well. Then, antibody-coated beads speciﬁ  c 
for the ten different cytokines were added to the 
wells and incubated for 2 h at room temperature 
in a shaker. After incubation, the plate was washed 
twice using a Manifold washer. Biotinylated anti-
bodies against the ten cytokines were added to the 
reaction and incubated during an hour. Afterwards, 
the cytokine-antibody complexes were detected by 
adding streptavidin coupled to phycoerythrin. The 
number of positive complexes was determined by 
reading each sample in a Luminex XYP platform. 
Data obtained in duplicates were analyzed using a 
MasterPlex 1.2 from Mai-Rabio, and data related 
to concentration was expressed in pg/ml.
Statistical analysis
Data are expressed as mean + SD. Means between 
study groups were compared using the two-tailed 354
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student’s t-test with unequal variance. Logistic 
regression analysis was utilized to identify a rela-
tionship between independent and dependent 
variables. A “p” value less than 0.05 was consid-
ered signiﬁ  cant. Each BALF sample was conducted 
in duplicate with consistent results.
Results
Utilizing a database which consisted of 260 LTX 
recipients, 13 recipients who developed histologic 
OB and also met criteria for BOS (OB group) were 
identiﬁ  ed, as were 21 recipients who never developed 
OB or BOS (non-OB group). The non-OB group 
consisted of all transplant recipients during the study 
period who: 1) never had histologic OB on lung 
biopsy, 2) did not fulﬁ  ll FEV1 criteria for BOS, 3) 
were free of pulmonary infection (as evidenced by 
negative BALF cultures) at the designated study time, 
and 4) had no evidence of acute allograft rejection 
(by biopsy) at the designated study time. As described 
in Table 1, recipients underwent single lung (n = 18), 
or bilateral lung (n = 16) transplantation for end-stage 
lung disease resulting from emphysema (n = 10), 
pulmonary ﬁ  brosis (n = 8), cystic ﬁ  brosis (n = 4), or 
pulmonary hypertension (n = 12).
In the OB/BOS group, a cross-sectional anal-
ysis was performed on BALF obtained during the 
most proximate bronchoscopy prior to the diag-
nosis of OB/BOS, at a time when subjects were 
clinically-well and free of OB, BOS, acute rejec-
tion, and infection. This occurred at median post-
op day 387 (range 45–2205) and corresponded to 
a median of 140 days (range 60–365) before the 
onset of OB/BOS. From among the serial lavage 
ﬂ  uid specimens of the non-OB group, the BALF 
selected for cross-sectional study was sampled at 
median post-op day 335 (range 270–395) when: 
1) subjects had no clinical evidence of allograft 
disease and 2) number of days post-op most 
closely matched that in the OB/BOS group.
Gelatinolytic activity in BALF of lung 
transplant recipients
The study of BALF by gelatin zymography revealed 
bands of degradation near 92 kD, corresponding to 
the puriﬁ  ed MMP-9 control. Compared to the non-
OB group, densitometric analysis of the zymogram 
of BALF samples from the OB group showed a 
nearly 20-fold increase in gelatinolytic activity per 
microgram of protein (p < 0.005) (Fig. 1).
Fibronectin gene transcription 
and TGF-β1 expression
Experiments were also conducted to ascertain if 
BALF contained soluble factors that could stimulate 
the production of extracellular matrix components 
like fibronectin, a matrix glycoprotein highly 
expressed in allograft rejection (Hirabayashi et al. 
1996). To this end, NIH3T3 ﬁ  broblasts permanently 
transfected with the human ﬁ  bronectin promoter 
connected to the luciferase reporter gene, 
pFN(1.2 kb)LUC, were cultured in the presence of 
BALF and processed for luciferase activity. As dem-
onstrated in Figure 2, ﬁ  bronectin promoter activity 
was present in control ﬁ  broblasts exposed to saline. 
The ﬁ  bronectin promoter activity was signiﬁ  cantly 
Table 1. Characteristics of study subjects.
Parameter Non-OB  OB/BOS
Lung  transplant diagnosis (n) 21  13
 Emphysema  6  4
 Pulmonary  ﬁ  brosis
  Idiopathic  0  3
  Collagen  vascular  disease-associated  4  1
 Cystic  ﬁ  brosis  2  2
 Pulmonary  hypertension
  Idiopathic  PAH  2  1
  Eisenmenger’s  syndrome  7  2
Bilateral lung transplant  10  6
Post-op days to OB/BOS diagnosis*   N/A  485 (73–2070)
Post-op day  BALF obtained*  335 (270–395)  387 (45–2205)
Days BALF collected before OB/BOS*  N/A  140 (60–365)
Abbreviations: OB: obliterative bronchiolitis; BOS: bronchiolitis obliterans syndrome; BALF: bronchoalveolar lavage ﬂ  uid.
*Values expressed as median (range).355
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greater after 72 hours in ﬁ  broblasts incubated with 
BALF from transplant recipients who later develop 
OB when compared to cells exposed to BALF from 
the non-OB group (p = 0.026).
The pro-fibrotic cytokine TGF-β1 has been 
implicated in the pathogenesis of OB and is a 
powerful regulator of fibronectin expression 
(Blobe et al. 2000). Consequently, the associa-
tion of TGF-β1 with fibronectin induction in 
OB was also examined. TGF-β1 protein levels 
were measured in BALF from the OB group by 
ELISA testing and a strong correlation between 
TGF-β1 protein levels and fibronectin gene 
transcription was found (r = 0.71) (Fig. 3). 
However, TGFβ1 levels, by themselves, were 
not found to be predictive of OB in this cohort 
(data not shown).
Cytokine levels in BALF
A multiplexed, fluorescent microsphere-based 
immunoassay was performed using the Luminex
® 
platform to quantify multiple cytokines simultane-
ously in each single sample. Microspheres were 
customized to detect the cytokines listed in Table 2. 
Of the ones measured, no differences in cytokine 
levels could be found in the BALF from the OB 
and non-OB groups. A trend toward statistical 
signiﬁ  cance was noted for interleukin-8 (IL-8) 
(p = 0.08). Interferon-γ, granulocyte-macrophage 
colony stimulating factor (GM-CSF), and interleu-
kin-5 could not be detected above background 
levels. Cytokine levels for each recipient were also 
individually analyzed. Representative graphs are 
depicted in Figure 4. Although no difference was 
seen in the amounts of IL-8 (shown), IL-6, IL-1β, 
and tumor necrosis factor-α, the same three 
recipients in the OB group had markedly elevated 
amounts of these cytokines in their BALF. In con-
trast, the level of IL-2 (shown), IL-4, and IL-10 in 
both groups were tightly clustered around the 
mean.
Discussion
The identiﬁ  cation of markers capable of predicting 
the development of OB in lung transplant recipients 
would have useful prognostic value, and would 
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Figure 1. Gelatinolytic activity is increased in the BALF of lung 
transplant recipients who later develop OB. Gelatin zymography 
performed on BALF specimens from lung transplant recipients 
revealed gelatinolytic activity at ~92 kD. Depicted is a representative 
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ﬁ  bronectin promoter-luciferase reporter construct were cultured with 
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ﬁ  broblasts exposed to BALF from the OB groups when compared to 
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serve to identify recipients who might beneﬁ  t from 
early intervention. Unfortunately, other than clinical 
risk factors such as repeated infections and early 
rejection, effective predictive factors for OB post 
lung transplantation are not available (Estenne et al. 
2002). Most studies in this area have focused on the 
inﬂ  ammatory cascade. For instance, BALF granu-
locytic markers, such as eosinophilia/neutrophilia, 
eosinophil cationic protein, and interleukin-6 (Riise 
et al. 1999) (Scholma et al. 2000), may herald the 
development of chronic allograft dysfunction, 
though, interestingly, they also represent biomarkers 
for acute cellular rejection, a well-established 
clinical risk factor for OB. Here, we focus on mark-
ers of tissue remodeling, another process known to 
be activated during tissue injury. In the lung, like 
other organs, activation of tissue remodeling is 
characterized by alterations in the expression or 
degradation of connective tissue matrices. Tissue 
remodeling is activated in lung rejection, and the 
pathologic features of OB reﬂ  ect its importance.
First described in the mid-1980’s (Burke et al. 
1984), histologic specimens obtained from affected 
recipients showed intraluminal granulation tissue 
and dense submucosal eosinophilic plaques. Oblit-
eration of the terminal airways by these lesions 
results in progressive airﬂ  ow obstruction. The 
observation that granulation tissue is deposited in 
the airways of recipients with OB has led to the 
suspicion that this ﬁ  nding represents a reparative 
response to some, as of yet, unidentiﬁ  ed injurious 
process. This initiating process is suspected of 
resulting in connective tissue remodeling thus 
culminating in the obliteration of terminal air-
ways. Obliterative bronchiolitis is characterized 
histologically, in part, by the deposition of colla-
gen matrix within the submucosa of terminal 
bronchioles. In contrast to normally occurring Type 
I collagen of healthy airways, porcine models of 
OB have demonstrated a predominance of Type III 
procollagen mRNA in airway ﬁ  broblasts suggest-
ing that ﬁ  broblast stimulation results in the deposi-
tion of collagen matrix (Alho et al. 2001). While 
several proﬁ  brotic mediators are suspected, the 
stimulus to this production of new matrix is 
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Table 2. Concentration of cytokines in bronchoalveolar lavage ﬂ  uid.
Cytokine   Non-OB  OB/BOS  p value
GM-CSF ND  ND –
Interferon-γ ND  ND  –
Interleukin-1β  20.32 ± 1.60  22.67 ± 6.76  0.24
Interleukin-2  25.07 ± 0.56  24.85 ± 0.16  0.14
Interleukin-4  30.11 ± 0.53  30.00 ± 0.50  0.53
Interleukin-5   ND  ND  –
Interleukin-6  13.83 ± 0.55  35.26 ± 51.69  0.16
Interleukin-8  9.46 ± 8.41  159.65 ± 281.53  0.08
Interleukin-10  16.67 ± 0.07  16.67 ±0.08  0.99
TNF-α  12.09 ± 0.66  14.19 ± 5.99  0.23
Abbreviations: OB: obliterative bronchiolitis; BOS: bronchiolitis obliterans syndrome; ND: not detectable; GM-CS: granulocyte-macrophage 
colony stimulating factor; TNF-α: tumor necrosis factor-alpha. Data are depicted as mean (pg/ml) ± SD.357
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unclear. This has prompted a search for proﬁ  brotic 
mediators in the airway of lung transplant recipi-
ents (Bergmann et al. 1998; Charpin et al. 1998).
In preliminary work generated from the analysis 
of BALF samples obtained at random from lung 
transplant recipients, we found that the early post-
surgical period (<3 months) is characterized by 
increased levels of gelatinolytic activity. This 
activity tended to decrease after this period, but 
remained elevated in recipients with OB when 
compared to those who remained stable (Boles and 
Roman, unpublished observations). These data 
suggested that gelatinolytic activity could serve as 
a predictor of OB development. However, the 
retrospective nature of this analysis did not allow 
for a careful characterization of the recipients, or 
for a thorough analysis of the data against 
parameters such as time of diagnosis of OB, among 
other factors.
To address these deﬁ  ciencies, we engaged in an 
analysis of samples collected from 260 recipients 
of lung transplantation. Within this group, we 
identiﬁ  ed a well-characterized subset of recipients 
who were subjected to bronchoscopy for surveil-
lance purposes prior to the diagnosis of OB 
(n = 13). Sequentially collected BALF samples 
were available from all of these recipients as well 
as from recipients who remained stable (n = 21). 
The BALF samples obtained from these recipients 
prior to the diagnosis of OB represent the experi-
mental material for this study.
We found increased gelatinolytic activity in the 
BALF of recipients who later developed OB. These 
data have important implications for the following 
reasons. First, the data were obtained using gelatin 
zymography, a simple yet effective method of 
detecting gelatinolytic activity that could be easily 
established in clinical laboratories. Second, the early 
detection of gelatinolytic activity might reflect 
important pathophysiological mechanisms that 
should be investigated. The activity detected was 
located at 92 kD consistent with active MMP-9. 
MMP-9 is a zinc-dependent endopeptidase that is 
secreted inactive from macrophages and epithelial 
cells, among other cells (Birkedal-Hansen et al. 
1993). Extracellular MMP-9 can be activated via 
proteolysis by other proteases including plasmin 
and other MMPs. Activated MMP-9 is capable of 
degrading type IV collagen, ﬁ  bronectin, elastin and 
other connective tissue matrices (Nagase and 
Woessner, 1999). It also can affect cellular chemo-
taxis and the activation of soluble growth factors 
such as TGF-β1. Rather than measuring MMP-9 
levels, we examined a functional property of 
MMP-9, i.e. gelatinase activity, as a marker of tissue 
remodeling since it not only incorporates the expres-
sion of active MMP-9, but reﬂ  ects the balance of 
MMP-9 activity and its inhibitor, TIMP-1.
The detection of increased levels MMP-9 in 
acute lung injury (Delclaux et al. 1997; Ricou et al. 
1996), idiopathic pulmonary ﬁ  brosis (Suga et al. 
2000), cystic ﬁ  brosis (Delacourt et al. 1995), 
bronchiectasis (Sepper et al. 1994), and other lung 
disorders characterizes MMP-9 as a sensitive 
marker of activation of tissue remodeling after 
lung injury, but it is unlikely to serve as a indica-
tor of a speciﬁ  c injurious agent or entity in the 
pathophysiology of many acute and chronic forms 
of disease. Among lung transplant recipients, 
MMP-9 has been found to be upregulated in BALF 
from those with BOS (Hubner et al. 2005; Taghavi 
et al. 2005). In our cohort of patients, we found 
that the gelatinolytic activity of MMP-9 in BALF 
was a strong predictor of both pulmonary function 
limitation and histologic airway ﬁ  brosis, suggesting 
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Figure 4. Cytokine levels in BALF of OB and non-OB samples. 
The analysis of cytokine levels in the BALF of individual recipients 
revealed that 3 of 13 recipients in the OB group had markedly elevated 
levels of IL-8 in their BALF. IL-1β, IL-6, and TNF-α had a similar pat-
tern in these recipients. In contrast, IL-2 levels were narrowly distrib-
uted about the mean in both groups. IL-4 and IL-10 expression were 
likewise similar.358
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a pathophysiological role for this protease linking 
the matrix remodeling to the airﬂ  ow obstruction 
in OB. Indeed, causality for MMP-9 in the patho-
genesis of OB has been proposed in studies using 
an animal model of chronic allograft rejection with 
MMP-9- deﬁ  cient mice (Fernandez et al. 2005).
We also found that the BALF obtained from 
recipients in the OB group stimulated the expres-
sion of ﬁ  bronectin in cultured ﬁ  broblasts. Fibro-
nectin is a matrix glycoprotein highly expressed 
in acute and chronic forms of lung injury; it, too, 
is considered an early marker of disease. Fibronectin 
is produced by ﬁ  broblasts, epithelial cells, and 
alveolar macrophages and the intact molecule or 
its fragments modulate cellular processes such as 
adhesion, migration/chemotaxis, proliferation, and 
in monocytic cells, cytokine expression (Roman, 
1998; Roman, 1996; Roman et al. 2000). The 
observed increase in its stimulation in the OB 
group, suggests that, like gelatinolytic activity, this 
molecule could serve as an early marker of injury 
that is likely to progress to OB.
Fibronectin expression is stimulated by a 
number of factors such as TGF-β1. The correlation 
between BALF levels of TGF-β1 protein and 
fibronectin stimulation in our assay suggest a 
causal role for TGF-β1. In other work, we 
demonstrate that interruption of TGF-β1 signaling 
through its intracellular signal transducer, Smad3, 
ameliorates experimental OB and results 
in decreased expression of ﬁ  bronectin (Ramirez 
et al. 2004).
In addition to the above, we evaluated the BALF 
samples for a number of cytokines. However, no 
statistically signiﬁ  cant differences were observed 
between the OB and non-OB groups. Only IL-8 
showed a trend towards signiﬁ  cance, and this is 
consistent with data from others showing upregu-
lation of IL-8 during episodes of ischemia-
reperfusion and active OB (De Perrot et al. 2002; 
DiGiovine et al. 1996). Although the number of 
patients tested was relatively small, our data, like 
that of DiGiovine et al.(DiGiovine et al. 1996), 
suggest that IL-8 and other cytokine measurements 
in BALF are not highly predictive markers of 
future development of OB. Indeed, consistently 
increased levels of IL-8 among cystic ﬁ  brosis 
recipients were not found to be associated with any 
allograft rejection (Dosanjh et al. 1998).
Together, our data suggest that OB in lung 
transplant recipients is preceded by the activation 
of tissue remodeling which can be detected in 
BALF as reﬂ  ected by increased gelatinolytic activ-
ity and BALF ability to stimulate fibronectin 
expression in ﬁ  broblasts. Further investigations 
will be needed to determine the true predictive 
value of these assays in lung transplant 
recipients.
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